286 related articles for article (PubMed ID: 18035201)
1. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis.
Breuer B; Pappagallo M; Knotkova H; Guleyupoglu N; Wallenstein S; Portenoy RK
Clin Ther; 2007 Sep; 29(9):2022-30. PubMed ID: 18035201
[TBL] [Abstract][Full Text] [Related]
2. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
3. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
4. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
Svendsen KB; Jensen TS; Bach FW
BMJ; 2004 Jul; 329(7460):253. PubMed ID: 15258006
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; OroĊska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
6. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study.
Silberstein SD; Hulihan J; Karim MR; Wu SC; Jordan D; Karvois D; Kamin M
Clin Ther; 2006 Jul; 28(7):1002-11. PubMed ID: 16990078
[TBL] [Abstract][Full Text] [Related]
8. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
Kivitz A; Ma C; Ahdieh H; Galer BS
Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
[TBL] [Abstract][Full Text] [Related]
11. Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain.
Silver M; Blum D; Grainger J; Hammer AE; Quessy S
J Pain Symptom Manage; 2007 Oct; 34(4):446-54. PubMed ID: 17662571
[TBL] [Abstract][Full Text] [Related]
12. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies.
Vinik AI; Tuchman M; Safirstein B; Corder C; Kirby L; Wilks K; Quessy S; Blum D; Grainger J; White J; Silver M
Pain; 2007 Mar; 128(1-2):169-79. PubMed ID: 17161535
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
[TBL] [Abstract][Full Text] [Related]
14. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
[TBL] [Abstract][Full Text] [Related]
15. A single-tablet fixed-dose combination of racemic ibuprofen/paracetamol in the management of moderate to severe postoperative dental pain in adult and adolescent patients: a multicenter, two-stage, randomized, double-blind, parallel-group, placebo-controlled, factorial study.
Mehlisch DR; Aspley S; Daniels SE; Southerden KA; Christensen KS
Clin Ther; 2010 Jun; 32(6):1033-49. PubMed ID: 20637958
[TBL] [Abstract][Full Text] [Related]
16. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis.
Cree BA; Kornyeyeva E; Goodin DS
Ann Neurol; 2010 Aug; 68(2):145-50. PubMed ID: 20695007
[TBL] [Abstract][Full Text] [Related]
17. Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial.
Lappin MS; Lawrie FW; Richards TL; Kramer ED
Altern Ther Health Med; 2003; 9(4):38-48. PubMed ID: 12868251
[TBL] [Abstract][Full Text] [Related]
18. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy.
Jose VM; Bhansali A; Hota D; Pandhi P
Diabet Med; 2007 Apr; 24(4):377-83. PubMed ID: 17335465
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis.
Falah M; Madsen C; Holbech JV; Sindrup SH
Eur J Pain; 2012 Jul; 16(6):860-9. PubMed ID: 22337561
[TBL] [Abstract][Full Text] [Related]
20. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
